Does the media favor SOPH or SDGR?

In the previous week, SOPHiA GENETICS had 2 more articles in the media than Schrodinger. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 5 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.17 beat SOPHiA GENETICS's score of 1.06 indicating that Schrodinger is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CERT or SOPH?

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Certara. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 2 mentions for Certara. SOPHiA GENETICS's average media sentiment score of 1.06 beat Certara's score of 1.04 indicating that SOPHiA GENETICS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Certara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SOPH or GDRX?

GoodRx has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SOPHiA GENETICS $86.17M 7.66 -$79M -$1.15 N/A GoodRx $785.23M 1.48 $30.44M $0.04 84.75

Is SOPH or GDRX more profitable?

GoodRx has a net margin of 2.07% compared to SOPHiA GENETICS's net margin of -93.86%. GoodRx's return on equity of 7.22% beat SOPHiA GENETICS's return on equity. Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS -93.86% -132.47% -45.97% GoodRx 2.07% 7.22% 2.53%

Does the media favor SOPH or GDRX?

In the previous week, SOPHiA GENETICS had 4 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 3 mentions for GoodRx. SOPHiA GENETICS's average media sentiment score of 1.06 beat GoodRx's score of 1.06 indicating that SOPHiA GENETICS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TDOC or SOPH?

In the previous week, SOPHiA GENETICS had 1 more articles in the media than Teladoc Health. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 6 mentions for Teladoc Health. Teladoc Health's average media sentiment score of 1.49 beat SOPHiA GENETICS's score of 1.06 indicating that Teladoc Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teladoc Health 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HSTM or SOPH?

In the previous week, SOPHiA GENETICS had 3 more articles in the media than HealthStream. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 4 mentions for HealthStream. HealthStream's average media sentiment score of 1.27 beat SOPHiA GENETICS's score of 1.06 indicating that HealthStream is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthStream 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SOPHiA GENETICS (SOPH) Competitors

$7.87 +0.26 (+3.42%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$7.86 0.00 (-0.06%)

As of 09/11/2026 07:30 PM Eastern

Compare

SOPH vs. SDGR, CERT, GDRX, TDOC, and HSTM

Should you buy SOPHiA GENETICS stock or one of its competitors? SOPHiA GENETICS's main competitors and comparable companies include Schrodinger (SDGR), Certara (CERT), GoodRx (GDRX), Teladoc Health (TDOC), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does SOPHiA GENETICS compare to Schrodinger?

SOPHiA GENETICS (NASDAQ:SOPH) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Schrodinger has a net margin of -20.98% compared to SOPHiA GENETICS's net margin of -93.86%. Schrodinger's return on equity of -16.37% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%
Schrodinger	-20.98%	-16.37%	-8.19%

SOPHiA GENETICS presently has a consensus price target of $10.00, indicating a potential upside of 27.06%. Schrodinger has a consensus price target of $20.50, indicating a potential upside of 7.78%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, research analysts plainly believe SOPHiA GENETICS is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Schrodinger	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, SOPHiA GENETICS had 2 more articles in the media than Schrodinger. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 5 mentions for Schrodinger. Schrodinger's average media sentiment score of 1.17 beat SOPHiA GENETICS's score of 1.06 indicating that Schrodinger is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SOPHiA GENETICS has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$86.17M	7.66	-$79M	-$1.15	N/A
Schrodinger	$259.04M	5.42	-$103.26M	-$0.74	N/A

SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Schrodinger beats SOPHiA GENETICS on 9 of the 15 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Certara?

Certara (NASDAQ:CERT) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Certara has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Certara has higher revenue and earnings than SOPHiA GENETICS. Certara is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$421.75M	2.73	-$1.60M	-$0.45	N/A
SOPHiA GENETICS	$86.17M	7.66	-$79M	-$1.15	N/A

Certara has a net margin of -16.75% compared to SOPHiA GENETICS's net margin of -93.86%. Certara's return on equity of 3.86% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Certara	-16.75%	3.86%	2.65%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

Certara presently has a consensus target price of $8.28, suggesting a potential upside of 9.64%. SOPHiA GENETICS has a consensus target price of $10.00, suggesting a potential upside of 27.06%. Given SOPHiA GENETICS's higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, SOPHiA GENETICS had 5 more articles in the media than Certara. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 2 mentions for Certara. SOPHiA GENETICS's average media sentiment score of 1.06 beat Certara's score of 1.04 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Certara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

74.0% of Certara shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 1.1% of Certara shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Certara beats SOPHiA GENETICS on 11 of the 17 factors compared between the two stocks.

How does SOPHiA GENETICS compare to GoodRx?

SOPHiA GENETICS (NASDAQ:SOPH) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

SOPHiA GENETICS has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

In the previous week, SOPHiA GENETICS had 4 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 3 mentions for GoodRx. SOPHiA GENETICS's average media sentiment score of 1.06 beat GoodRx's score of 1.06 indicating that SOPHiA GENETICS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 5.9% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GoodRx has a net margin of 2.07% compared to SOPHiA GENETICS's net margin of -93.86%. GoodRx's return on equity of 7.22% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%
GoodRx	2.07%	7.22%	2.53%

GoodRx has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$86.17M	7.66	-$79M	-$1.15	N/A
GoodRx	$785.23M	1.48	$30.44M	$0.04	84.75

SOPHiA GENETICS presently has a consensus price target of $10.00, indicating a potential upside of 27.06%. GoodRx has a consensus price target of $4.23, indicating a potential upside of 24.70%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

GoodRx beats SOPHiA GENETICS on 11 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to Teladoc Health?

Teladoc Health (NYSE:TDOC) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

76.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 0.7% of Teladoc Health shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Teladoc Health has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, SOPHiA GENETICS had 1 more articles in the media than Teladoc Health. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 6 mentions for Teladoc Health. Teladoc Health's average media sentiment score of 1.49 beat SOPHiA GENETICS's score of 1.06 indicating that Teladoc Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teladoc Health	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teladoc Health presently has a consensus target price of $7.54, indicating a potential upside of 22.37%. SOPHiA GENETICS has a consensus target price of $10.00, indicating a potential upside of 27.06%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than Teladoc Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

SOPHiA GENETICS has lower revenue, but higher earnings than Teladoc Health. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.49B	0.45	-$200.32M	-$0.99	N/A
SOPHiA GENETICS	$86.17M	7.66	-$79M	-$1.15	N/A

Teladoc Health has a net margin of -7.13% compared to SOPHiA GENETICS's net margin of -93.86%. Teladoc Health's return on equity of -12.15% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-7.13%	-12.15%	-5.83%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

Summary

Teladoc Health beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.

How does SOPHiA GENETICS compare to HealthStream?

HealthStream (NASDAQ:HSTM) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, SOPHiA GENETICS had 3 more articles in the media than HealthStream. MarketBeat recorded 7 mentions for SOPHiA GENETICS and 4 mentions for HealthStream. HealthStream's average media sentiment score of 1.27 beat SOPHiA GENETICS's score of 1.06 indicating that HealthStream is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthStream	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HealthStream has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than HealthStream, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$321.12M	2.65	$18.34M	$0.72	40.43
SOPHiA GENETICS	$86.17M	7.66	-$79M	-$1.15	N/A

HealthStream has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

HealthStream has a net margin of 6.60% compared to SOPHiA GENETICS's net margin of -93.86%. HealthStream's return on equity of 6.81% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.60%	6.81%	4.64%
SOPHiA GENETICS	-93.86%	-132.47%	-45.97%

HealthStream currently has a consensus price target of $27.00, indicating a potential downside of 7.25%. SOPHiA GENETICS has a consensus price target of $10.00, indicating a potential upside of 27.06%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
SOPHiA GENETICS	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

69.6% of HealthStream shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 20.4% of HealthStream shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

HealthStream beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.

Get SOPHiA GENETICS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOPH vs. The Competition

Export

Metric	SOPHiA GENETICS	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$638.44M	$1.69B	$7.16B	$12.73B
Dividend Yield	N/A	4.69%	2.56%	11.15%
P/E Ratio	-6.84	20.39	274.10	25.29
Price / Sales	7.66	87.95	656.00	99.06
Price / Cash	N/A	31.50	77.04	51.44
Price / Book	11.41	5.96	10.33	6.20
Net Income	-$79M	-$18.66M	$3.50B	$358.50M
7 Day Performance	-2.72%	-1.52%	-3.35%	-2.35%
1 Month Performance	3.96%	3.60%	-0.43%	-2.77%
1 Year Performance	152.24%	-14.71%	19.21%	7.63%

SOPHiA GENETICS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOPH SOPHiA GENETICS	3.5079 of 5 stars	$7.87 +3.4%	$10.00 +27.1%	+145.9%	$638.44M	$86.17M	N/A	520	News Coverage Positive News
SDGR Schrodinger	1.4629 of 5 stars	$20.84 +6.9%	$20.50 -1.6%	+1.3%	$1.44B	$255.87M	N/A	790	Positive News
CERT Certara	1.5774 of 5 stars	$8.10 -2.3%	$8.28 +2.2%	-30.9%	$1.26B	$418.84M	N/A	1,576	Positive News
GDRX GoodRx	4.6104 of 5 stars	$3.46 -0.9%	$4.23 +22.2%	-19.7%	$1.20B	$796.85M	86.52	950	Positive News
TDOC Teladoc Health	2.759 of 5 stars	$6.25 -1.4%	$7.54 +20.6%	-20.7%	$1.15B	$2.53B	N/A	5,600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SOPH) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does SOPHiA GENETICS compare to Schrodinger?

Summary

How does SOPHiA GENETICS compare to Certara?

Summary

How does SOPHiA GENETICS compare to GoodRx?

Summary

How does SOPHiA GENETICS compare to Teladoc Health?

Summary

How does SOPHiA GENETICS compare to HealthStream?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SOPHiA GENETICS (SOPH) Competitors

SOPH vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does SOPHiA GENETICS compare to Schrodinger?

Is SOPH or SDGR more profitable?

Do analysts rate SOPH or SDGR?

Does the media favor SOPH or SDGR?

Which has stronger earnings & valuation, SOPH or SDGR?

Which has more risk and volatility, SOPH or SDGR?

Do insiders & institutionals believe in SOPH or SDGR?

Summary

How does SOPHiA GENETICS compare to Certara?

Which has more volatility & risk, CERT or SOPH?

Which has preferable valuation & earnings, CERT or SOPH?

Is CERT or SOPH more profitable?

Do analysts recommend CERT or SOPH?

Does the media refer more to CERT or SOPH?

Do insiders & institutionals have more ownership in CERT or SOPH?

Summary

How does SOPHiA GENETICS compare to GoodRx?

Which has more volatility and risk, SOPH or GDRX?

Does the media favor SOPH or GDRX?

Do institutionals and insiders have more ownership in SOPH or GDRX?

Is SOPH or GDRX more profitable?

Which has stronger earnings and valuation, SOPH or GDRX?

Do analysts rate SOPH or GDRX?

Summary

How does SOPHiA GENETICS compare to Teladoc Health?

Do insiders and institutionals hold more shares of TDOC or SOPH?

Which has more risk and volatility, TDOC or SOPH?

Does the media refer more to TDOC or SOPH?

Do analysts prefer TDOC or SOPH?

Which has higher valuation & earnings, TDOC or SOPH?

Is TDOC or SOPH more profitable?

Summary

How does SOPHiA GENETICS compare to HealthStream?

Does the media refer more to HSTM or SOPH?

Which has stronger valuation and earnings, HSTM or SOPH?

Which has more volatility and risk, HSTM or SOPH?

Is HSTM or SOPH more profitable?

Do analysts prefer HSTM or SOPH?

Do insiders & institutionals hold more shares of HSTM or SOPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH vs. The Competition

SOPHiA GENETICS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools